An Early Phase 1 interventional study of Ovidrel and Placebo in Traumatic Brain Injury, sponsored by VA Office of Research and Development. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by VA Office of Research and Development · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development — 8 open to participants now, 8 under way, none of them phase 3. Brain Injuries, Traumatic · VA Office of Research and Development.
Among the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development, this one is the 28th largest by planned enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2027, is one of 3 in phase 1, and was the 55th registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →8 of the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18–65
VA Office of Research and Development · Sites in United States
Ages 18–89
VA Office of Research and Development · Sites in United States
Ages 22–65
VA Office of Research and Development · Sites in United States
Ages 18–65
VA Office of Research and Development · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 65 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 52 across 1,091 interventional studies indexed under Brain Injuries, Traumatic.
Median enrollment 61 across the 46 interventional studies, 91 across the 9 observational. Of the 43 that completed or were terminated, 34 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
3 of the studies in Brain Injuries, Traumatic by VA Office of Research and Development that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02920788VA Office of Research and DevelopmentMild TBI Assessment & Rehabilitation | 2026-12-31 |
| NCT05776056VA Office of Research and DevelopmentMethylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints | 2027-03-31 |
| NCT04003285VA Office of Research and DevelopmentAllopregnanolone in Chronic Complex Traumatic Brain Injury | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 55 studies in Brain Injuries, Traumatic by VA Office of Research and Development, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The COGNI-REHAB Trial is a single-site, phase O/I, randomized, double-blind, placebo-controlled study of human chorionic gonadotropin (hCG; choriogonadotropin alfa, Ovidrel®) in men with post-acute, moderate to severe traumatic brain injury (msTBI). Its objective is to assess the safety and efficacy of a 24-week regimen of Ovidrel (125 micrograms twice weekly) compared to placebo on treatment-emergent adverse events (TEAEs), cognitive and functional recovery, and circulating sex hormones.
This project aims to re-purpose a safe, well-tolerated, already-approved medication: human chorionic gonadotropin (hCG; choriogonadotropin alfa, Ovidrel®) for use in the post-acute rehabilitation of moderate to severe traumatic brain injury (msTBI). Ovidrel is currently FDA-approved for use in ovulation induction and Assisted Reproductive Technologies (ART). The rationale for using Ovidrel comes from a convergence of evidence indicating that hCG has neurodevelopmental and neuroregenerative properties, and from preclinical studies demonstrating that hCG reverses TBI-induced suppression of sex hormone production (i.e., reverses hypogonadism) and improves recovery of sensorimotor and spatial learning and memory in rodents following a focal injury to the medial prefrontal cortex. Recovery from a TBI is typically a very slow process because innate neuronal regeneration is a slow process; thus, Ovidrel (125 µg twice weekly) treatment will be evaluated over 24-weeks in patients that are 1-6 months post-TBI.
The criteria were revised on the registry on Oct 13, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ovidrel: 125 micrograms in 0.25 milliliters (mL) administered subcutaneously twice weekly for 24 weeks
Drug: Ovidrel
Placebo: 0.25 milliliters (mL) of sterile normal saline administered subcutaneously twice weekly for 24 weeks
Other: Placebo
Ovidrel, recombinant human chorionic gonadotropin, comes in a prefilled syringe for subcutaneous injection, is the investigational agent that will be used in this trial. Ovidrel® PreFilled Syringe is a sterile, liquid intended for subcutaneous (s.c.) injection. Each Ovidrel® PreFilled Syringe is filled with 0.515 milliliters (mL) containing 257.5 micrograms of choriogonadotropin alfa, 28.1 milligrams (mg) mannitol, 505 grams (g) 85% O-phosphoric acid, 103 grams (g) L-methionine, 51.5 g Poloxamer 188, Sodium Hydroxide (for pH adjustment), and Water for Injection to deliver 125 micrograms of choriogonadotropin alfa in 0.25 milliliters (mL) twice weekly. The pH of the solution is 6.5 to 7.5.
Also known as: Choriogonadotropin alfa
Prefilled syringe of 0.250 milliliters (mL) normal saline.
Percent change in Treatment-Emergent Adverse Events
The frequency and type of individual TEAEs, discontinuations due to TEAEs, serious TEAEs, and clinically significant changes in laboratory test values.
Time frame: Baseline, 26 Weeks
Percent change in modified Functional Independence Measure (FIM)
The FIM is a standardized rating of motor and cognitive disability is commonly used to guide and track progress during rehabilitation, drilling down into level of assistance required for various daily tasks.
Time frame: Baseline, 24 Weeks
Glasgow Outcome Scale-Extended (GOSE)
The GOSE is a brief standardized tool developed for assessing TBI severity and recovery, offering a useful global indicator of disability severity.
Time frame: Baseline, 24 Weeks
Percent Change in Neuropsychiatric Inventory (NPI)
The NPI measures psychopathology in patients with neurological disorders, this tool allows brief screening of different conditions. When a screening item is positive, it follows up with more detail of symptom types, frequency, severity, and how distressing it is to caregivers. This makes for a very efficient and useful tool, providing a more comprehensive assessment of symptoms when they are present, and can be used to track recovery.
Time frame: Baseline, 24 Weeks
Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)
This standardized self-rated scale detects presence and severity of PTSD symptoms and is used for monitoring during recovery. This is widely used in the veteran TBI literature as PTSD is frequently comorbid with TBI and can complicate recovery. This is a necessary complement to the NPI, which doesn't assess PTSD.
Time frame: Baseline, 24 Weeks
Percent change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
RBANS is used in msTBI to assess cognitive impairment and track recovery in rehabilitation, this performance-based test generates a Total cognition score, which is made up of indices of Attention, Learning, Memory, Language, and Visuospatial skills. Each index can be broken down into two or more different aspects of the given cognitive domain. This allows for both global and more fine-grained analysis of cognitive impairment and recovery.
Time frame: Baseline, 24 Weeks
Percent change in Automated Neuropsychological Assessment Metrics Military (ANAM)
ANAM is used by the US military to assess cognitive function in service members for pre-deployment screening, post-injury monitoring, TBI detection and recovery. This test complements the RBANS by offering a measure of reaction time and more robust assessment of processing speed and executive functions.
Time frame: Baseline, 24 Weeks
Percent change in Trail Making Test (TMT)
TMT is a test of simple psychomotor speed and complex attention / executive control. It requires less manual dexterity than the RBANS and is less complicated by reaction time than the ANAM, so is useful in a mixed msTBI population as some participants may also have motor disability.
Time frame: Baseline, 24 Weeks
Columbia-Suicide Severity Rating Scale (C-SSRS)
The "Columbia Protocol" is a brief tool used by healthcare professionals to identify if a person is at risk for suicide.
Time frame: Baseline, 26 Weeks
Change in Circulating Sex Hormone Concentrations
Percent change in circulating sex hormone concentrations.
Time frame: Baseline, 26 Weeks
Plan to share: Yes — The data and resources sharing plan for this project is in accordance with the Veterans Administration Data Sharing Policies. All raw clinical, genetic, and imaging data from this project will be available upon written request. Deidentified data may be uploaded to one or more of several available data sharing sites designed for this purpose. The final data will be available in acceptable formats such as presentations and publications. Research data and results that document and support the study aims will be available after the final results are accepted for publication. The data to be shared will be anonymized and there will be no fees or other restrictions.
Supporting information: Study protocol, Informed consent form
Time frame: Research data and results that document and support the study aims will be available after the final results are accepted for publication.
Access criteria: Approval from PI
Start is estimated for Jan 2027; primary completion for Oct 2029, 33 months later.
Of 27 phase 1 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 66. This study's planned 33 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Oct 2026 → Jan 2027, primary completion Jul 2029 → Oct 2029 and completion Sep 2029 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ovidrel
VA Office of Research and Development →